FORA Capital LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,610 shares of the medical equipment provider's stock, valued at approximately $4,745,000. Intuitive Surgical makes up about 0.8% of
Banque Transatlantique SA boosted its stake in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 18.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 160,131 shares of the medical equipment provider's stock after purchasing an additional 25,462 shares during the period. Intuitive
2Xideas AG raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 11.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,764 shares of the medical equipment provider's stock after buying an additional 1,102 shares during the
In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $472.16, denoting a -1.48% move from the preceding trading day.
The average of price targets set by Wall Street analysts indicates a potential upside of 29.7% in Intuitive Surgical (ISRG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $479.27, marking a -2.76% move from the previous day.
ISRG targets cardiac surgery as a long-term da Vinci 5 growth driver after FDA clearance, eyeing nearly 160,000 potential procedures in cleared markets vs approximately 17,000 today.
Intuitive Surgical is initiated with a Buy rating and a $584.87 price target, reflecting 19% upside potential. ISRG's business model benefits from robust recurring revenues in consumables and services, with continued growth in robotic surgery adoption and international expansion. Margins faced temporary pressure from tariffs and the Da Vinci 5 rollout, but operating margins remained resilient and are expected to stabilize by 2026.
Intuitive Surgical (ISRG) remains the robotic-assisted surgery market leader, with Q4 procedures up 18% and revenue rising 19% to $2.87 billion. ISRG's recurring revenue model, high margins, and $3B net cash underpin a robust balance sheet and significant moat. Despite strong fundamentals, ISRG trades at a P/E of 63 versus its 53.5 historical average, justifying a Hold rating amid recent technical weakness.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.